Babatunde Oyajobi, Ph.D.Associate Professor
The University of Sheffield, Sheffield, England, 1992
We are particularly interested in the translation of novel insights into the biology of MM-induced bone disease into therapies for patients and employ a variety of complementary in vitro and in vivo approaches. As part of this effort and in collaboration with other groups, we are currently refining existing mouse models of cancer-induced bone diseases (primarily MM and breast cancer) as well as developing and characterizing newer models that are better at predicting anti-tumor and anabolic bone efficacy of novel compounds. An example of this is the Radl 5T model of MM that we developed that replicates many of the features seen in the human disease. In this model, when murine 5TGM1 myeloma cells genetically engineered to express either green fluorescent protein (GFP) or luciferase are injected intravenously in naïve syngeneic C57BL/kaLwRijHsd mice, they home to the skeleton where they form tumors in the medullary cavities (Oyajobi et al., 2007).
Dr. Oyajobi is Course co-Director on two cross-listed Responsible Conduct of Research (RCR) courses (INTD 5082/TSCI 5070), the only institution-wide courses that meet current NIH guidelines on RCR.These courses, which are open to all graduate and other health profession students engaged in research activities serve several graduate programs including the Integrated Biomedical Sciences (IBMS), Radiological Sciences, PhD in Translational Sciences, Joint UTHSCSA-UTSA PhD in Biomedical Engineering, PhD in Nursing, MD/PhD and DDS/PhD programs as well as various MS programs (Cell Systems & Anatomy, Clinical Investigation-Translational Sciences, Immunology & Infection).
Dr. Oyajobi also teaches on, and co-directs the Interdisciplinary Human Gross Anatomy Course (CSBL 5022) for graduate students in the MS in Cell Systems & Anatomy, IBMS and Biomedical Engineering Graduate Programs as well as for health profession students in the Occupational Therapy (OT), Physical Therapy (PT), Physician Assistant Studies (PAS) programs. He is also a lecturer on other graduate school courses including the Cancer Biology Core I Course (CSBL 6068).
Dr. Oyajobi has been honored for his contributions by the CSA department with the 2013 Award for Excellence in Graduate Student Education.
Sharma R,* Williams PJ,* Gupta A, McCluskey B, Bhaskaran S, Muñoz S, Oyajobi BO. A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. (*Equal contribution). Oncotarget. 2015 Aug 28;6(25):21589-602.
De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget. 2015 Apr 30;6(12):10532-47.
Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV, Oyajobi BO. PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells. Leukemia. 2014 Oct;28(10):2080-9.
Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012 Aug 16;120(7):1449-57.
Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, Carew JS, Nawrocki ST. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012 Jun 21;31(25):3023-38.
Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Muñoz S, Zhao M, Mundy GR. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol. 2007 Nov;139(3):434-8.
Oyajobi BO, Muñoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR.
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther. 2007 Jun;6(6):1701-8.